Pharmacyclics Update (9-10-14)

Special Update – PCYC Scores VA Contract, PCYC Shares Still Undervalued – In breaking news, PCYC has been awarded a large Veterans Affairs (VA) contract for Imbruvica.   Details – VA – A Large Buying Group: The following information was posted today (dated September 4, 2014)   Solicitation Number: VA797P14R0033 Contract Award Date: September 4,[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue #784 – Q2:14 Results & Outlook

August 7, 2014 Below is a pdf for MTSL Issue #784 of the Medical Technology Stock Letter.   [gview file=http://www.bioinvest.com/wp-content/uploads/2014/08/MTSL-784-August-7-2014.pdf save=”1″]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Dick Davis Investment Digest (7-23-14)

July 23, 2014 Mid-Year Top Picks for 2014 Written By Nancy Zambell Welcome to the Investment Digest Mid-Year Top Picks for 2014! This issue is our Mid-Year Top Picks Update. Many of our contributors’ recommendations returned double-digit gains so far this year. We’ve included sell recommendations on a few picks and six new Top Picks[…]

Posted on by

The Life Sciences Report (6-19-14)

June 19, 2014 Fire Up the Immuno-Oncology Powerhouses: by : Editors, The Life Sciences Report Forecasting when we’ll have a cure for cancer remains beyond the predictive powers of researchers and investors. But forecasting the focus of the latest American Society of Clinical Oncology meeting was in the cards: Immuno-oncology took center stage. In this[…]

Posted on by

U~T San Diego Isis Pharmaceuticals (9-3-14)

September 3, 2014 ISIS Heart Drugs Get Good News Drugmaker’s News Encouraging Written By Bradley J. Fikes Strengthening the outlook for its drug development pipeline, Isis Pharmaceuticals has announced progress with two of its flagship cardiovascular drugs. On Tuesday, the Carlsbad biotech presented evidence that an already-approved drug, Kynamro, dramatically reduces risk of heart attacks.[…]

Posted on by

Biotech Fund Managers – What The Pros Do Every Year

August 21, 2014 The Medical Technology Stock Letter (“MTSLâ€) prides itself on identifying exciting small companies that will become leaders in their respective fields over time. We emphasize “over time†because that is the nature of drug development and compounded returns of successful biotech stocks over the years vastly exceed that of the overall market. […]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue #782 – Deals, Data & IPOs Lead Solid End Of Q2

July 3, 2014 Below is a pdf for MTSL Issue #782 of the Medical Technology Stock Letter.   [gview file=http://www.bioinvest.com/wp-content/uploads/2014/07/MTSL-_782-July-3-2014.pdf save=”1″]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

A BRIEF IMMUNE-ONCOLOGY UPDATE

June 12, 2014 ASCO 2014 – Immune Oncology Rises to the Top – As many expected, immune oncology (I-O) was all the rage at the recently concluded American Society of Clinical Oncology (ASCO) meeting.  While it is widely acknowledged that before ASCO, Bristol was the leader in the space followed by Merck, and Roche.  At[…]

Posted on by

MTSL Issue #783 – MTSL Portfolio H2:14 Event Calendar

July 17, 2014 Below is a pdf for MTSL Issue #783 of the Medical Technology Stock Letter.   [gview file=http://www.bioinvest.com/wp-content/uploads/2014/07/MTSL-783-July-17-2014.pdf save=”1″]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Pharmacyclics Update (7-23-14)

SPECIAL UPDATE – PCYC – GILD Severely Restrictive Zydelig Label Underscores Imbruvica’s Superior Profile – Reiterate BUY – Gilead received approval midday for Zydelig (idelalisib) for three blood cancers – refractory CLL, indolent FL and SLL – some what ahead of the August/September PDUFA dates.  While the approvals were widely expected, the strict BLACK BOX[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue #781 – A BRIEF IMMUNE-ONCOLOGY UPDATE

June 12, 2014 Below is a pdf for MTSL Issue #781 of the Medical Technology Stock Letter.   [gview file= http://www.bioinvest.com/wp-content/uploads/2014/06/MTSL-781-June-12-2014-1.pdf =”1″]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by